Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$547.03−0.86 (-0.16%)
Close on Nov 11, 2026Market cap $138.65BP/E 31.8Yield –
Vertex Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vertex Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was $5.00B, up 21.2% year over year. For fiscal 2025 it was $4.38B. The highest annual figure on record is $4.46B in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.38B | – |
| FY2024 | Dec 31, 2024 | -$25.70M | -100.6% |
| FY2023 | Dec 31, 2023 | $4.01B | -9.9% |
| FY2022 | Dec 31, 2022 | $4.46B | +53.2% |
| FY2021 | Dec 31, 2021 | $2.91B | -2.0% |
| FY2020 | Dec 31, 2020 | $2.97B | +127.4% |
| FY2019 | Dec 31, 2019 | $1.30B | +84.3% |
| FY2018 | Dec 31, 2018 | $707.57M | +283.2% |
| FY2017 | Dec 31, 2017 | $184.64M | +158.8% |
| FY2016 | Dec 31, 2016 | $71.33M | – |
| FY2015 | Dec 31, 2015 | -$404.54M | – |
| FY2014 | Dec 31, 2014 | -$629.16M | – |
| FY2013 | Dec 31, 2013 | -$561.64M | -761.4% |
| FY2012 | Dec 31, 2012 | $84.92M | -43.0% |
| FY2011 | Dec 31, 2011 | $148.86M | – |
| FY2010 | Dec 31, 2010 | -$665.62M | – |
| FY2009 | Dec 31, 2009 | -$583.91M | – |
| FY2008 | Dec 31, 2008 | -$430.51M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.30B | +8.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.19B | +76.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.26B | +17.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.24B | +6.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.20B | – |
| Q1 FY2025 | Mar 31, 2025 | $678.50M | -43.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.07B | +2.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.17B | +8.3% |
| Q2 FY2024 | Jun 30, 2024 | -$3.46B | -424.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.19B | +45.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.05B | -2.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.08B | -7.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.07B | -6.6% |
| Q1 FY2023 | Mar 31, 2023 | $817.80M | -24.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.07B | +17.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.16B | +7.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.14B | – |
| Q1 FY2022 | Mar 31, 2022 | $1.08B | +17.5% |
| Q4 FY2021 | Dec 31, 2021 | $911.50M | +17.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.09B | +55.4% |
| Q2 FY2021 | Jun 30, 2021 | -$6.60M | -100.9% |
| Q1 FY2021 | Mar 31, 2021 | $916.60M | +22.7% |
| Q4 FY2020 | Dec 31, 2020 | $775.13M | +34.2% |
| Q3 FY2020 | Sep 30, 2020 | $698.88M | +458.3% |
| Q2 FY2020 | Jun 30, 2020 | $744.73M | +150.2% |
| Q1 FY2020 | Mar 31, 2020 | $747.05M | +145.8% |
| Q4 FY2019 | Dec 31, 2019 | $577.68M | +294.2% |
| Q3 FY2019 | Sep 30, 2019 | $125.18M | -44.3% |
| Q2 FY2019 | Jun 30, 2019 | $297.66M | +55.9% |
| Q1 FY2019 | Mar 31, 2019 | $303.95M | +109.3% |
| Q4 FY2018 | Dec 31, 2018 | $146.55M | +3.1% |
| Q3 FY2018 | Sep 30, 2018 | $224.84M | – |
| Q2 FY2018 | Jun 30, 2018 | $190.94M | +182.5% |
| Q1 FY2018 | Mar 31, 2018 | $145.24M | -49.2% |
| Q4 FY2017 | Dec 31, 2017 | $142.17M | +158.1% |
| Q3 FY2017 | Sep 30, 2017 | -$310.82M | – |
| Q2 FY2017 | Jun 30, 2017 | $67.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $285.69M | – |
| Q4 FY2016 | Dec 31, 2016 | $55.09M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.16M | – |
See a number that looks wrong?